caspofungin
ApprovedUNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Invasive Pulmonary Aspergillosis
Conditions
Invasive Pulmonary Aspergillosis, Chronic Obstructive Pulmonary Disease
Trial Timeline
Jan 1, 2012 → Nov 1, 2014
NCT ID
NCT01499433About caspofungin
caspofungin is a approved stage product being developed by Merck for Invasive Pulmonary Aspergillosis. The current trial status is unknown. This product is registered under clinical trial identifier NCT01499433. Target conditions include Invasive Pulmonary Aspergillosis, Chronic Obstructive Pulmonary Disease.
What happened to similar drugs?
3 of 20 similar drugs in Invasive Pulmonary Aspergillosis were approved
Approved (3) Terminated (2) Active (16)
🔄Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel + Epirubicin or doxorubicin, cyclophosphamide, paclitaxelJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
20
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02596984 | Pre-clinical | Completed |
| NCT01499433 | Approved | UNKNOWN |
| NCT01318148 | Phase 2 | Completed |
| NCT01165320 | Phase 2 | Completed |
| NCT01260974 | Phase 2 | UNKNOWN |
| NCT00333645 | Phase 2 | UNKNOWN |
Competing Products
20 competing products in Invasive Pulmonary Aspergillosis